젬백스
082270KOSDAQ특수 목적용 기계 제조업46.0 / 100
Reference Date: 2026-06-10
Company InformationBased on 2025 Annual Report
Business Overview
jemBucks operates two main business segments: an environmental pollution control division producing chemical filters and air purification systems for semiconductor and display manufacturing, and a biotech division conducting clinical trials for GV1001, a telomerase-derived peptide drug candidate for Alzheimer's disease. The environmental division accounts for 99.2% of 2024 sales with its flagship product, the Chemical Air Filter, while the biotech division focuses on developing next-generation peptide drugs based on GV1001's anti-inflammatory and neuroprotective properties.
Number of Employees
217people
Average Salary
46.9M KRW
Score Calculation Basis
Detailed Financial Score
Well below industry avg
8.2x industry avg (risky)
Avg ▲8.4% (2-year basis)
Avg ▼138.7% (2-year basis)
Avg ROE -58.7% (declining, 3yr)
Detailed News Sentiment
- Positive[단독] 남경필 전 경기지사, 젬백스앤카엘 회장 취임…17일 한국거래소...
남경필 전 지사의 취임으로 젬백스앤카엘의 리더십 변화가 긍정적인 시장 반응을 이끌 것으로 예상됩니다.
- Neutral젬백스, 70억 규모 전환사채권 발행 결정
젬백스가 운영자금 조달을 위해 전환사채 발행을 결정했으나, 구체적인 시장 영향은 제한적이다.
Detailed Momentum
Near 52w low (0%, downtrend)
1m -37.12% (strong drop)
Volume flat
Detailed Disclosure
- Neutral주식등의대량보유상황보고서(일반)2026-06-05
- Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-06-02
- Neutral증권발행결과(자율공시)2026-06-01
- Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-06-01
- Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-05-22
